Showing results (491-500 of 654) with videos related to
Sort By:
Pageof 66
Journal of Diabetes and Its Complications|October 29, 2024
Effects of probiotics and fibers on markers of nephropathy, inflammation, intestinal barrier dysfunction and endothelial dysfunction in individuals with type 1 diabetes and albuminuria. The ProFOS StudyElisabeth B Stougaard, Ninna Hahn Tougaard, Suvanjaa Sivalingam, et al.Journal of General Internal Medicine|December 15, 2023
Effects of Dapagliflozin in Chronic Kidney Disease Across the Spectrum of Age and by SexMargaret K Yu, Priya Vart, Niels Jongs, et al.European Journal of Preventive Cardiology|June 27, 2017
Epicardial, pericardial and total cardiac fat and cardiovascular disease in type 2 diabetic patients with elevated urinary albumin excretion rateRegitse H Christensen, Bernt J von Scholten, Christian S Hansen, et al.Kidney International Reports|March 8, 2022
The Kidney Protective Effects of the Sodium-Glucose Cotransporter-2 Inhibitor, Dapagliflozin, Are Present in Patients With CKD Treated With Mineralocorticoid Receptor AntagonistsMichele Provenzano, Niels Jongs, Priya Vart, et al.JAMA|September 2, 2015
Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical TrialGeorge L Bakris, Rajiv Agarwal, Juliana C Chan, et al.Diabetes Technology & Therapeutics|October 24, 2024
Possible Glycemic Effects of Vagus Nerve Stimulation Evaluated by Continuous Glucose Monitoring in People with Diabetes and Autonomic Neuropathy: A Randomized, Sham-Controlled TrialHuda Kufaishi, Davide Bertoli, Ditte Smed Kornum, et al.Journal of the American Society of Nephrology : JASN|August 17, 2022
Correlates and Consequences of an Acute Change in eGFR in Response to the SGLT2 Inhibitor Dapagliflozin in Patients with CKDNiels Jongs, Glenn M Chertow, Tom Greene, et al.Nature Reviews. Nephrology|April 3, 2024
Combination therapy for kidney disease in people with diabetes mellitusDaniël H van Raalte, Petter Bjornstad, David Z I Cherney, et al.Journal of the American College of Cardiology|January 6, 2026
Risk of Hyperkalemia With Empagliflozin, Finerenone, or Both: Secondary Analysis of the CONFIDENCE Randomized TrialRajiv Agarwal, Jennifer B Green, Hiddo J L Heerspink, et al.Diabetes, Obesity & Metabolism|July 7, 2023
Overall and inter-individual effect of four different drug classes on soluble urokinase plasminogen activator receptor in type 1 and type 2 diabetesViktor Rotbain Curovic, Morten B Houlind, Marjolein Y A M Kroonen, et al.Pageof 66